WO1995017154A3 - Use of thalidomide for treating neurocognitive disorders - Google Patents

Use of thalidomide for treating neurocognitive disorders Download PDF

Info

Publication number
WO1995017154A3
WO1995017154A3 PCT/US1994/014743 US9414743W WO9517154A3 WO 1995017154 A3 WO1995017154 A3 WO 1995017154A3 US 9414743 W US9414743 W US 9414743W WO 9517154 A3 WO9517154 A3 WO 9517154A3
Authority
WO
WIPO (PCT)
Prior art keywords
thalidomide
treating
neurocognitive disorders
cholinergic deficit
treatment
Prior art date
Application number
PCT/US1994/014743
Other languages
French (fr)
Other versions
WO1995017154A2 (en
Inventor
Peter J Andrulis Jr
Original Assignee
Andrulis Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrulis Pharm Corp filed Critical Andrulis Pharm Corp
Priority to EP95904954A priority Critical patent/EP0735874A1/en
Priority to AU13751/95A priority patent/AU1375195A/en
Publication of WO1995017154A2 publication Critical patent/WO1995017154A2/en
Publication of WO1995017154A3 publication Critical patent/WO1995017154A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Abstract

A method for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state.
PCT/US1994/014743 1993-12-23 1994-12-22 Use of thalidomide for treating neurocognitive disorders WO1995017154A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95904954A EP0735874A1 (en) 1993-12-23 1994-12-22 Use of thalidomide for treating neurocognitive disorders
AU13751/95A AU1375195A (en) 1993-12-23 1994-12-22 Use of thalidomide for treating neurocognitive disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/172,155 1993-12-23
US08/172,155 US5434170A (en) 1993-12-23 1993-12-23 Method for treating neurocognitive disorders

Publications (2)

Publication Number Publication Date
WO1995017154A2 WO1995017154A2 (en) 1995-06-29
WO1995017154A3 true WO1995017154A3 (en) 1995-07-13

Family

ID=22626590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/014743 WO1995017154A2 (en) 1993-12-23 1994-12-22 Use of thalidomide for treating neurocognitive disorders

Country Status (4)

Country Link
US (1) US5434170A (en)
EP (1) EP0735874A1 (en)
AU (1) AU1375195A (en)
WO (1) WO1995017154A2 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739109A (en) * 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
IT1276031B1 (en) * 1995-10-31 1997-10-24 Angelini Ricerche Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO1997045117A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6255347B1 (en) 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
DK1586322T3 (en) * 1996-11-05 2008-12-01 Childrens Medical Center Compositions containing thalidomide and dextamethasone for the treatment of cancer
FR2756737B1 (en) * 1996-12-05 1999-01-08 Rhone Poulenc Rorer Sa APPLICATION OF THALIDOMIDE TO THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES
US6664239B2 (en) * 1997-05-06 2003-12-16 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
AU7237198A (en) * 1997-05-21 1998-12-11 Shionogi & Co., Ltd. Remedies for dementia of alzheimer type containing gamma-sultam derivatives
DE19743968C2 (en) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenous application form of thalidomide for the therapy of immunological diseases
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6458777B1 (en) 1998-03-13 2002-10-01 Mucosal Therapeutics Llc Methods and compositions for treating and preventing mucositis
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6440967B1 (en) * 1998-11-12 2002-08-27 Merck & Co., Inc. Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
WO2002005634A2 (en) 2000-07-13 2002-01-24 University Of South Florida Transgenic animal and methods
WO2002064083A2 (en) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1389203B8 (en) * 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US20030164219A1 (en) * 2002-02-20 2003-09-04 Joerg Brahm Headliner/duct assembly and welding process therefor
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0207529D0 (en) * 2002-04-02 2002-05-08 Norbrook Lab Ltd Injectable veterinary composition for small animals
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
US9006267B2 (en) * 2002-11-14 2015-04-14 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
US20060188512A1 (en) * 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2007502332A (en) * 2003-05-30 2007-02-08 マイクロバイア インコーポレイテッド Memory and cognitive protection law
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
SG133603A1 (en) 2003-09-17 2007-07-30 Us Gov Health & Human Serv Thalidomide analogs as tnf-alpha modulators
CA2543312A1 (en) * 2003-10-24 2005-05-06 Celgene Corporation Methods and compositions comprising thalidomide for treatment of fibromyalgia
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
WO2005102345A1 (en) * 2004-03-30 2005-11-03 Alcon, Inc. Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (en) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Veneers for walls, retaining walls and the like.
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
PE20061329A1 (en) 2004-12-15 2006-12-08 Neuralab Ltd HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
ES2396555T3 (en) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Antibodies that recognize beta amyloid peptide
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
EP2134323A4 (en) * 2007-04-06 2012-03-07 Rhode Island Education Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20170044096A1 (en) 2013-03-15 2017-02-16 Rutgers, The State University Of New Jersey Augmenting Moieties for Anti-Inflammatory Compounds
US11731991B2 (en) 2008-11-03 2023-08-22 Lehigh University Augmenting moieties for anti-inflammatory compounds
WO2010051044A1 (en) * 2008-11-03 2010-05-06 University Of Medicine And Dentistry Unique dual-action therapeutics
JP5339588B2 (en) * 2008-11-10 2013-11-13 国立大学法人 新潟大学 A therapeutic drug for schizophrenia containing thalidomide or its derivatives as an active ingredient
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
WO1995004533A2 (en) * 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830991A (en) * 1954-05-17 1958-04-15 Gruenenthal Chemie Products of the amino-piperidine-2-6-dione series
ATE63903T1 (en) * 1984-10-25 1991-06-15 Hoechst Roussel Pharma 9-AMINO-1,2,3,4-TETRAHYDROACRIDIN-1-OL AND RELATED COMPOUNDS, PROCESSES FOR THEIR MANUFACTURE AND USE AS MEDICINAL PRODUCTS.
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
US5210087A (en) * 1991-02-13 1993-05-11 Hoechst-Roussel Pharmaceuticals Inc. 9-aminotetrahydroacridines and related compounds
TW239127B (en) * 1991-12-20 1995-01-21 Hoffmann La Roche

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
WO1995004533A2 (en) * 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. FILLIT: "Elevated circulating tumor necrosis factor levels in Alzheimer's disease", NEUROSCI. LETTERS, vol. 129, no. 2, 1991, pages 318 - 320 *
P.L. MCGEER: "Anti-inflammatory drugs and Alzheimer disease.", THE LANCET, vol. 335, no. 8696, 1990, pages 1037 *
S.S. HENDLER: "Thalidomide for autoimmune disease", MED. HYPOTHESES, vol. 10, no. 4, 1983, pages 437 - 443 *

Also Published As

Publication number Publication date
WO1995017154A2 (en) 1995-06-29
EP0735874A1 (en) 1996-10-09
AU1375195A (en) 1995-07-10
US5434170A (en) 1995-07-18

Similar Documents

Publication Publication Date Title
WO1995017154A3 (en) Use of thalidomide for treating neurocognitive disorders
US5037384B1 (en) Method and apparatus for the treatment of complicated retinal detachments
EP0727985A4 (en) Composition and method for treating blood vessel disorders of the skin using vitamin k
DE58902094D1 (en) COMBINATION DEVICE FOR THE TREATMENT OF NERVOUS AND NERVE FIBER DISEASES AND INJURIES.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69739792D1 (en) Method for the treatment of eye diseases
EP1366770A3 (en) Use of botulinum toxin for treating muscle-associated pain
AU6760987A (en) Method of treating alzheimer's disease
ATE213411T1 (en) USE OF PHENSERINE IN THE PRODUCTION OF MEDICATIONS FOR THE TREATMENT OF COGNITIVE DISORDERS
ATE281840T1 (en) TREATMENT OF DIARRHEA
EP0651650A4 (en) METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b).
DK0723444T3 (en) Levobupivacaine suitable for the treatment of chronic pain
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
HU891056D0 (en) Process for treating the diseases of the gullet and the stomach-intestine system
NZ324615A (en) Method for treating autism using olanzapine
PL335802A1 (en) Method of treating vascular disorders
Sykes et al. The use of group therapy in the treatment of bulimia.
DE68909750D1 (en) DEVICE FOR THE THERAPEUTIC TREATMENT OF LUMBAGO AND LUMBAGO / ISCHIAS.
EP0745597A3 (en) Novel melatonergic indanyl piperazines or homopiperazines
DE3585312D1 (en) APPLICATION OF 1,6-DIMETHYL-4-OXO-1,6,7,8,9A-HEXAHYDRO-4H-PYRIDO (1,2-A) PYRIMIDIN-3-CARBOXAMIDE FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DAMAGE.
RU93057223A (en) METHOD OF TREATMENT OF PARALISES AND PARESIS
CA2147749A1 (en) Therapeutic agent for diseases of periodontal tissue
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
RU93037466A (en) METHOD FOR TREATING PERIPHERAL NEUROPATHIES
ATE79759T1 (en) COMBINATION MEDICATION FOR THE TREATMENT OF NERVE CELL AND NERVE FIBER DISEASES AND INJURIES.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995904954

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995904954

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995904954

Country of ref document: EP